Comparison 1. Rho kinase inhibitor versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Mean intraocular pressure (IOP) changes from baseline	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1.1 Netarsudil 0.02% once per day	3	155	Mean Difference (IV, Random, 95% CI)	‐3.11 [‐3.62, ‐2.59]
1.1.2 Ripasudil 0.4% twice per day	1	103	Mean Difference (IV, Random, 95% CI)	‐1.30 [‐2.15, ‐0.45]
1.2 Mean IOP changes from baseline: sensitivity analysis	3		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.2.1 Netarsudil 0.02% once per day	2	119	Mean Difference (IV, Fixed, 95% CI)	‐2.96 [‐3.56, ‐2.37]
1.2.2 Ripasudil 0.4% twice per day	1	103	Mean Difference (IV, Fixed, 95% CI)	‐1.30 [‐2.15, ‐0.45]
1.3 Total ocular adverse events (per person‐month) – incidence risk difference	5		Risk Difference (IV, Random, 95% CI)	0.66 [0.28, 1.03]
1.3.1 Netarsudil 0.02% once per day	4		Risk Difference (IV, Random, 95% CI)	0.86 [0.38, 1.34]
1.3.2 Ripasudil 0.4% twice per day	1		Risk Difference (IV, Random, 95% CI)	0.27 [0.13, 0.41]
1.4 Total ocular adverse events (per person‐month): sensitivity analysis	2		Risk Difference (IV, Random, 95% CI)	0.67 [0.55, 0.79]
1.5 Conjunctival hyperemia as adverse event (per person‐month)*	5		Risk Difference (IV, Random, 95% CI)	0.46 [0.19, 0.73]
1.5.1 Ripasudil 0.4% twice per day	1		Risk Difference (IV, Random, 95% CI)	0.26 [0.14, 0.38]
1.5.2 Netarsudil 0.02% once per day	4		Risk Difference (IV, Random, 95% CI)	0.79 [0.16, 1.42]
1.6 Ocular pain or irritation as adverse event (per person‐month)*	5		Risk Difference (IV, Random, 95% CI)	0.04 [‐0.07, 0.15]
1.6.1 Ripasudil 0.4% twice per day	1		Risk Difference (IV, Random, 95% CI)	0.01 [‐0.05, 0.07]
1.6.2 Netarsudil 0.02% once per day	4		Risk Difference (IV, Random, 95% CI)	0.08 [‐0.14, 0.30]